IL249436B - Use of dextran sulfate with an average molecular weight below 10,000 daltons to encourage the formation of new blood vessels in a patient - Google Patents

Use of dextran sulfate with an average molecular weight below 10,000 daltons to encourage the formation of new blood vessels in a patient

Info

Publication number
IL249436B
IL249436B IL249436A IL24943616A IL249436B IL 249436 B IL249436 B IL 249436B IL 249436 A IL249436 A IL 249436A IL 24943616 A IL24943616 A IL 24943616A IL 249436 B IL249436 B IL 249436B
Authority
IL
Israel
Prior art keywords
angiogenisis
inducing
subject
molecular weight
average molecular
Prior art date
Application number
IL249436A
Other languages
English (en)
Hebrew (he)
Other versions
IL249436A0 (en
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451120A external-priority patent/SE538144C2/sv
Priority claimed from PCT/SE2015/050677 external-priority patent/WO2015190989A1/en
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of IL249436A0 publication Critical patent/IL249436A0/en
Publication of IL249436B publication Critical patent/IL249436B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
IL249436A 2014-06-12 2016-12-07 Use of dextran sulfate with an average molecular weight below 10,000 daltons to encourage the formation of new blood vessels in a patient IL249436B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1450729 2014-06-12
SE1451120A SE538144C2 (sv) 2014-06-12 2014-09-22 Use of dextran sulfate for inducing angiogenesis
SE1451540 2014-12-15
PCT/SE2015/050677 WO2015190989A1 (en) 2014-06-12 2015-06-11 The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject

Publications (2)

Publication Number Publication Date
IL249436A0 IL249436A0 (en) 2017-02-28
IL249436B true IL249436B (en) 2019-07-31

Family

ID=57575349

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249436A IL249436B (en) 2014-06-12 2016-12-07 Use of dextran sulfate with an average molecular weight below 10,000 daltons to encourage the formation of new blood vessels in a patient

Country Status (21)

Country Link
US (2) US10485817B2 (ru)
EP (1) EP3154551B1 (ru)
JP (1) JP6557683B2 (ru)
KR (1) KR102015197B1 (ru)
CN (1) CN106573012B (ru)
AU (1) AU2015272115B2 (ru)
BR (1) BR112016029008B1 (ru)
CA (1) CA2951686C (ru)
DK (1) DK3154551T3 (ru)
EA (1) EA032569B1 (ru)
ES (1) ES2705069T3 (ru)
HR (1) HRP20190051T1 (ru)
IL (1) IL249436B (ru)
MX (1) MX363122B (ru)
MY (1) MY178989A (ru)
NZ (1) NZ727008A (ru)
PH (1) PH12016502435A1 (ru)
PL (1) PL3154551T3 (ru)
PT (1) PT3154551T (ru)
SG (1) SG11201610142PA (ru)
ZA (1) ZA201700134B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE538503C2 (en) * 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) * 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用
AU2018329430B2 (en) * 2017-09-08 2024-05-02 Tx Medic Ab New use of dextran sulfate
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5945547B2 (ja) 1977-01-31 1984-11-07 豊田合成株式会社 ステアリングホイ−ル
DE3634392A1 (de) 1986-10-09 1988-04-14 Knoll Ag Verwendung polysulfatierter niedermolekularer dextransulfate
US5135920A (en) 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
IT1264530B (it) 1992-07-31 1996-10-02 Crinos Industria Farmaco Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
WO1999017784A1 (en) * 1997-10-07 1999-04-15 Regents Of The University Of California Corporation Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
US6106554A (en) * 1999-02-25 2000-08-22 Bausch & Lomb Surgical, Inc. Intraocular lens implants for the prevention of secondary cataracts
US20030171287A1 (en) * 2000-06-27 2003-09-11 Ryuichi Morishita Medicinal compositions for angiogenic therapy
JP5030124B2 (ja) * 2000-12-21 2012-09-19 竜一 森下 血管新生療法用医薬組成物
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
JP2006134692A (ja) * 2004-11-05 2006-05-25 Toppan Printing Co Ltd リチウム電池用外装材
CN101232897A (zh) 2005-06-16 2008-07-30 新藤隆行 含有肾上腺髓质素作为有效成分的血管生成剂
CA2685208C (en) * 2007-04-24 2014-04-08 Novelmed Therapeutics, Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
JP5612279B2 (ja) * 2009-06-26 2014-10-22 日本合成化学工業株式会社 心筋梗塞非ヒト動物モデル及びその作製方法

Also Published As

Publication number Publication date
MY178989A (en) 2020-10-26
KR102015197B1 (ko) 2019-08-27
US10485817B2 (en) 2019-11-26
MX363122B (es) 2019-03-11
EP3154551A4 (en) 2017-12-27
CN106573012A (zh) 2017-04-19
EP3154551B1 (en) 2018-10-10
IL249436A0 (en) 2017-02-28
PT3154551T (pt) 2019-01-18
BR112016029008A2 (pt) 2017-08-22
EA032569B1 (ru) 2019-06-28
ES2705069T3 (es) 2019-03-21
JP2017518322A (ja) 2017-07-06
CA2951686A1 (en) 2015-12-17
CA2951686C (en) 2019-05-21
US10925890B2 (en) 2021-02-23
DK3154551T3 (en) 2019-01-28
JP6557683B2 (ja) 2019-08-07
HRP20190051T1 (hr) 2019-03-08
EP3154551A1 (en) 2017-04-19
SG11201610142PA (en) 2017-01-27
NZ727008A (en) 2020-05-29
EA201692555A1 (ru) 2017-04-28
US20170151275A1 (en) 2017-06-01
MX2016016312A (es) 2017-08-28
KR20170045195A (ko) 2017-04-26
BR112016029008B1 (pt) 2023-05-02
CN106573012B (zh) 2020-02-28
PH12016502435B1 (en) 2017-03-06
AU2015272115A1 (en) 2016-12-22
US20190381090A1 (en) 2019-12-19
PH12016502435A1 (en) 2017-03-06
ZA201700134B (en) 2018-04-25
AU2015272115B2 (en) 2019-01-17
PL3154551T3 (pl) 2019-05-31

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HRP20190051T1 (hr) Uporaba dekstran sulfata koji ima prosječnu molekularnu masu ispod 10000 da za induciranje angiogeneze kod subjekta
GB201418171D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
HRP20190073T1 (hr) Novi dekstran sulfat
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL251976A0 (en) Phage therapy
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
IL248608A0 (en) Sulphites of hyperane
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL246729B (en) Anti-growth preparations for coating tubers and onions and their use for anti-growth treatment
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
GB201506491D0 (en) The ashley easy exercise chair
Macknik et al. In Plain Sight
GB201415760D0 (en) "The eCV" or "eCV"
GB201521588D0 (en) Fft 1
GB201511757D0 (en) The "i-wheel"
GB2524711B (en) Builder's hawk
GB201416686D0 (en) Cine 8
TH1501007339A (th) ที่นอนปรับสมดุลที่กระจายแรงโน้มถ่วงของร่างกายมนุษย์
GB201400612D0 (en) The Edwards 'Chronometer'
GB201412275D0 (en) Lock 'n' level

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed